Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:

NCT ID: NCT01976923 Completed - Clinical trials for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The purpose of this is study is to assess the efficacy of pre-operative intravitreal bevacizumab (IVB) (Genentech, South San Francisco CA) in improving visual acuity, reducing operative time, complications, intra-operative and post-operative hemorrhage following small gauge pars plana vitrectomy (PPV) (23-gauge, 25-gauge or 27-gauge ) compared to small gauge PPV (23-gauge, 25-gauge or 27-gauge) alone in eyes with tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy (PDR). Hypothesis: Preoperative IVB may be beneficial for membrane dissection in diabetic tractional retinal detachment with minimally invasive vitreoretinal surgery (23-gauge transconjunctival sutureless vitrectomy [TSV]). In addition, post-operative rebleeding may be decreased.

NCT ID: NCT01976468 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The "SCOPE-ITSCC Metastases Study"

Start date: November 2013
Phase:
Study type: Observational

The investigators hypothesize that a low number of SCC in OTR will metastasize.

NCT ID: NCT01974804 Completed - Brain Cancer Clinical Trials

Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis

Start date: October 25, 2013
Phase:
Study type: Observational

Magnetic resonance imaging (MRI) is a diagnostic study that makes pictures of organs of the body using magnetic field and radio frequency pulses that can not be felt. The purpose of this study is to determine if new imaging methods can help tumor evaluation in the brain. The extra images will be obtained using diffusion and perfusion MRI techniques to assess early treatment response in patients with brain metastasis, and will be compared to methods currently being used.

NCT ID: NCT01972503 Recruiting - Clinical trials for Colorectal Neoplasms

Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer

Start date: June 2008
Phase: Phase 4
Study type: Interventional

In this study, the investigators assessed whether intraoperative Intraportal infusion of 5-FU and oxaliplatin is able to prevent liver metastasis in patients receiving curative colorectal cancer resection.

NCT ID: NCT01972490 Completed - Clinical trials for Colorectal Neoplasms

Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Start date: October 2013
Phase: Phase 4
Study type: Interventional

In this study, the investigators assessed the effect of avastin in combination with chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited metastases

NCT ID: NCT01970644 Terminated - Neoplasm Metastases Clinical Trials

Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases

Start date: April 2014
Phase: N/A
Study type: Observational

Cancer which spreads to the brain (brain metastases) is a common and significant problem. Historically, whole-brain radiotherapy has been used to treat these patients but has a negative effect on cognition. Radiosurgery is an alternative treatment with potential for fewer cognitive side effects. The impact of radiosurgery alone on the cognitive function of patients with multiple brain metastases is not well studied. We propose a pilot study at the Winnipeg Centre for Gamma Knife Surgery to examine this issue.

NCT ID: NCT01965223 Completed - Cancer Clinical Trials

A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)

SAFRON II
Start date: February 4, 2015
Phase: N/A
Study type: Interventional

The main purpose of this study is to determine the safety (defined as number of participants experiencing ≥ 5% toxicity at 12 months post treatment) of stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung.

NCT ID: NCT01964677 Completed - Cancer Clinical Trials

MR-HIFU for Bone Metastases

Start date: January 2014
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate effectiveness of the Philips Sonalleve MR-HIFU device for the palliation of pain in patients with bone metastases. Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound (MR-HIFU) uses ultrasound to palliate pain caused by bone metastases. The main palliative mechanism of the method is due to local bone denervation, caused by the heat denaturation of the periosteum layer in the treated area. The importance of this therapy is that it offers a non-invasive, focal therapy, avoiding side-effects to surrounding normal tissue that occur with radiation therapy or the need for needle insertion as with radio-frequency(RF)ablation. The study hypothesis is that MR-HIFU will be effective in treating the pain associated with bone metastases

NCT ID: NCT01962376 Recruiting - Gastric Cancer Clinical Trials

Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis

Start date: February 2013
Phase: Phase 4
Study type: Interventional

The investigators assessed whether the addition of a preoperative regimen of Bevacizumab regimen to improves R0 resection rate and survival among patients with potentially resectable gastric cancer with liver metastasis.

NCT ID: NCT01960829 Recruiting - Melanoma Clinical Trials

Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study

Start date: September 2013
Phase: Phase 2
Study type: Interventional

This is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety. The study objective is to evaluate efficacy profile of everolimus. The patients who comply with the inclusion and exclusion criteria will be enrolled. The estimated recruiting duration is 18 months. Everolimus will be given in the dose of 10 mg orally each day at lease 6 months unless disease progression or intolerance. The follow-up is till death(at least 1 year).